asthma
Table of Contents
asthma
see also:
diagnosis in adults
- Spirometry is the preferred initial test to assess the presence and severity of airflow obstruction
- PEFR testing: PEF should be recorded as the best of three forced expiratory blows from total lung capacity with a maximum pause of two seconds before blowing. The patient can be standing or sitting. Further blows should be done if the largest two PEF are not within 40 l/min.
suggestive features
- More than one of the following symptoms: wheeze, breathlessness, chest tightness and cough, particularly if:
- symptoms worse at night and in the early morning
- symptoms in response to exercise, allergen exposure and cold air
- symptoms after taking aspirin or beta blockers
- History of atopic disorder
- Family history of asthma and/or atopic disorder
- Widespread wheeze heard on auscultation of the chest
- Otherwise unexplained low FEV1 or PEF (historical or serial readings)
- Otherwise unexplained peripheral blood eosinophilia
features that lower the probability of asthma
- Prominent dizziness, light-headedness, peripheral tingling
- Chronic productive cough in the absence of wheeze or breathlessness
- Repeatedly normal physical examination of chest when symptomatic
- Voice disturbance
- Symptoms with colds only
- Significant smoking history (ie >20 pack-years)
- Cardiac disease
- Normal PEF or spirometry when symptomatic
- NB. a normal spirogram/spirometry when not symptomatic does not exclude the diagnosis of asthma. Repeated measurements of lung function are often more informative than a single assessment.
further Ix
- if airway obstruction present:
- if spirometry/PEFR indicate airway obstruction (FEV1 / FVC < 0.7) but Dx of asthma is only intermediate probability:
- test for reversibility of obstruction or commence a trial of SABA with oral prednisolone 30 mg daily for two weeks, and if beneficial, Rx as for asthma
- a >400 ml improvement in FEV1 to either β2 agonists or corticosteroid treatment trials strongly suggests underlying asthma
- but if not trial not beneficial, Ix for other causes of airway obstruction such as:
- inhaled foreign body
- obliterative bronchiolitis
- large airway stenosis
- if no evidence of airway obstruction (FEV1 / FVC > 0.7)
- if Dx of asthma is only intermediate probability, then refer for further Ix such as:
- tests of airway responsiveness:
- Methacholine PC20 challenge (the provocative concentration of methacholine required to cause a 20% fall in FEV1)
- exercise challenge in untreated patients
- tests for eosinophilic airway inflammation:
- FENO (exhaled nitric oxide concentration)
- Sputum eosinophil count
- consider DDx such as:
- Chronic cough syndromes
- Hyperventilation syndrome
- Vocal cord dysfunction
clinical control of asthma
- the Global Initiative for Asthma (GINA) defines clinical control as:
- twice a week or less daytime symptoms or need for reliever
- no limitation of actvities including exercise
- no night time asthma symptoms
- normal or near-normal lung function
- no exacerbations
stepwise Rx of the adult asthmatic
- see acute asthma in the adult patient for severe acute attacks requiring ED presentations
step 1. mild asthma
- short acting inhaled beta 2 adrenergic agonists (SABA) prn for symptom relief
step 2. mild asthma with frequent symptoms
- for example:
- exacerbations of asthma within past 2 years
- symptomatic or needing to use SABA 3x a week or more
- waking more than one night a week due to asthma
- add a low dose inhaled corticosteroids preventer (ICS) such as (adult doses provided):
- beclometasone 200mcg bd (eg. QVar)
- budesonide 200mcg bd (eg. Pulmicort)
- fluticasone 125mcg bd (eg. Flixotide)
- mometasone 100mcg bd
- ciclesonide 100mcg bd
- for those unable to use ICS, consider:
- sodium cromoglicate which is of some benefit in adults and is effective in children aged 5-12, or,
- leukotriene receptor antagonists have been shown to have some beneficial clinical effect
- especially useful for children under 5 years
step 3. poor control despite step 2 Mx
- consider either:
- increase ICS dose from low to medium dose (ie. double the dose), OR,
- continue low dose ICS but add a long acting inhaled beta 2 adrenergic agonists (LABA), OR,
- switch to a ICS-LABA FDC formulation, for example:
- budesonide/eformoterol (eg. Symbicort turbuhaler 100/6 bd)
- fluticasone/salmeterol (eg. Seretide MDI 50/25 bd or Seretide Accuhaler 100/50 bd)
- fluticasone/eformoterol (eg. Flutiform 50/5 bd)
step 4. severe asthma
- consider either:
- if on medium dose ICS dose add a LABA, OR,
- if on low dose ICS plus LABA, increase to medium dose ICS plus LABA OR,
- if on ICS-LABA FDC formulation, consider higher dose FDC formulations such as
- budesonide/eformoterol (eg. Symbicort turbuhaler 200/6 bd)
- fluticasone/salmeterol (eg. Seretide MDI 100/25 bd or Seretide Accuhaler 200/50 bd)
- fluticasone propionate - eformoterol fumarate dihydrate (eg. Flutiform 100/10 bd)
future potential medications
references
asthma.txt · Last modified: 2019/05/17 08:41 by 127.0.0.1